Penland, Robert C. http://orcid.org/0000-0003-2706-8913
Åstrand, Magnus
Boulton, David W.
Någård, Mats
Funding for this research was provided by:
AstraZeneca
Article History
Accepted: 13 February 2024
First Online: 19 March 2024
Declarations
:
: AstraZeneca sponsored the underlying clinical studies and this analysis.
: RCP, MÅ, DWB, MN: are employees of, and hold stock in, AstraZeneca.
: Data underlying the findings described in this manuscript may be requested in accordance with AstraZeneca’s data sharing policy, described at . AstraZeneca Group of Companies allows researchers to submit a request to access anonymized patient level clinical data, aggregate clinical or genomics data (when available), and anonymized clinical study reports through the Vivli web-based data request platform.
: All studies were conducted in accordance with the ethical principles set forth in the Declaration of Helsinki, the International Conference on Harmonisation guideline regarding Good Clinical Practice (E6 Consolidated Guidance, April 1996), and the ethical requirements referred to in the European Union Directive 2001/20/EC. The institutional review boards or ethics committees of the study sites approved the study protocols. Informed consent was obtained from all individual participants included in the studies.
: Informed consent was obtained from all individual participants included in the studies.
: Not applicable.
: The representative NONMEM control stream can be made available by contacting the corresponding author.
: Study conception and design: RCP, MÅ, DWB, MN. Material preparation: RCP, MÅ. Data collection and statistical analysis: RCP, MÅ. All authors critically reviewed the manuscript for important intellectual content and approved the final manuscript.